These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12067907)

  • 21. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
    Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
    Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist.
    Komesli S; Vivien D; Dutartre P
    Eur J Biochem; 1998 Jun; 254(3):505-13. PubMed ID: 9688260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of liver fibrosis in aryl hydrocarbon receptor null mice by dietary vitamin A depletion.
    Andreola F; Calvisi DF; Elizondo G; Jakowlew SB; Mariano J; Gonzalez FJ; De Luca LM
    Hepatology; 2004 Jan; 39(1):157-66. PubMed ID: 14752834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.
    Angelov SN; Hu JH; Wei H; Airhart N; Shi M; Dichek DA
    Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2102-2113. PubMed ID: 28729364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of a soluble transforming growth factor beta type II receptor on the activation of rat hepatic stellate cells in primary culture.
    Cui X; Shimizu I; Lu G; Itonaga M; Inoue H; Shono M; Tamaki K; Fukuno H; Ueno H; Ito S
    J Hepatol; 2003 Nov; 39(5):731-7. PubMed ID: 14568254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers.
    Stockwell BR; Schreiber SL
    Curr Biol; 1998 Jun; 8(13):761-70. PubMed ID: 9651680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
    Motomura Y; Kanbayashi H; Khan WI; Deng Y; Blennerhassett PA; Margetts PJ; Gauldie J; Egashira K; Collins SM
    Am J Physiol Gastrointest Liver Physiol; 2005 Jan; 288(1):G143-50. PubMed ID: 15297261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melittin inhibits TGF-β-induced pro-fibrotic gene expression through the suppression of the TGFβRII-Smad, ERK1/2 and JNK-mediated signaling pathway.
    Park SH; Cho HJ; Jeong YJ; Shin JM; Kang JH; Park KK; Choe JY; Park YY; Bae YS; Han SM; Moon SK; Kim WJ; Choi YH; Chang YC
    Am J Chin Med; 2014; 42(5):1139-52. PubMed ID: 25178280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy.
    Yata Y; Gotwals P; Koteliansky V; Rockey DC
    Hepatology; 2002 May; 35(5):1022-30. PubMed ID: 11981752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology.
    Calabrese F; Valente M; Giacometti C; Pettenazzo E; Benvegnu L; Alberti A; Gatta A; Pontisso P
    J Gastroenterol Hepatol; 2003 Nov; 18(11):1302-8. PubMed ID: 14535988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HuangQi Decoction Ameliorates Renal Fibrosis via TGF-β/Smad Signaling Pathway In Vivo and In Vitro.
    Zhao J; Wang L; Cao AL; Jiang MQ; Chen X; Wang Y; Wang YM; Wang H; Zhang XM; Peng W
    Cell Physiol Biochem; 2016; 38(5):1761-74. PubMed ID: 27161221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
    Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
    Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice.
    Inoue S; Egashira K; Ni W; Kitamoto S; Usui M; Otani K; Ishibashi M; Hiasa K; Nishida K; Takeshita A
    Circulation; 2002 Nov; 106(21):2700-6. PubMed ID: 12438296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
    Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity.
    Ihling C; Technau K; Gross V; Schulte-Mönting J; Zeiher AM; Schaefer HE
    Atherosclerosis; 1999 May; 144(1):7-14. PubMed ID: 10381272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
    Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
    Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable.
    Levéen P; Larsson J; Ehinger M; Cilio CM; Sundler M; Sjöstrand LJ; Holmdahl R; Karlsson S
    Blood; 2002 Jul; 100(2):560-8. PubMed ID: 12091349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.